NIAID RSVF2-5
NIAID RSVF2-5 is a human monoclonal antibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSV subgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
In Vitro
NIAID RSVF2-5 neutralizes RSV Tracy (subgroup A) and RSV 18537 (subgroup B) in HEp-2 cells with IC50 values of 3.6 μg/mL and 1.8 μg/mL, respectively[2].
NIAID RSVF2-5 neutralizes RSV A2 (subgroup A) in HEp-2 cells with an IC60 of 0.07 μg/mL[2].
NIAID RSVF2-5 binds to purified RSV A2 strain gF protein with a KD of 4.9 × 10-10 M[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
NIAID RSVF2-5 (5-15 mg/kg; i.p. or i.m.; single dose; 1 day prior to challenge) significantly reduces lung viral titers in RSV-challenged cotton rats when administered prophylactically[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (female, 42 weeks old, average weight 25 g) intranasally inoculated with RSV strain A2[1]
-
Dosage:0.0039; 0.0156; 0.0625; 0.25; 1.0; 4.0 mg/kg
-
Administration:i.n.; single dose; on day 4 after infection
-
Result:Achieved a 2000-fold reduction in mean lung RSV titer (to 1.9 log10 pfu/g) with virus detected in only 1 of 6 animals at 4.0 mg/kg; reduced mean nasal turbinate RSV titer to 3.2 log10 pfu/g at 4.0 mg/kg.
Reduced mean lung RSV titer to 3.3 log10 pfu/g and mean nasal turbinate RSV titer to 3.8 log10 pfu/g at 1.0 mg/kg.
Reduced mean lung RSV titer to 4.3 log10 pfu/g and mean nasal turbinate RSV titer to 4.4 log10 pfu/g at 0.25 mg/kg.
Reduced mean lung RSV titer to 4.0 log10 pfu/g and mean nasal turbinate RSV titer to 4.2 log10 pfu/g at 0.0625 mg/kg.
Showed no significant reduction in lung or nasal turbinate RSV titers relative to untreated controls at 0.0156 mg/kg and 0.0039 mg/kg.
-
Animal Model:Sigmodon hispidis (60-125 g) intranasally administered with RSV[2]
-
Dosage:15; 5 mg/kg (i.p.); 12 mg/kg (i.m.)
-
Administration:i.p. or i.m.; single dose 1 day prior to challenge
-
Result:Showed no significant reduction in nasal titer at 15 mg/kg (i.p.), with nasal titer measured at 4.95 log10 total PFU.
Reduced lung titer by 0.93 log10 (9-fold) from control at 15 mg/kg (i.p.), with lung titer at 3.96 log10 PFU/g.
Showed no significant reduction in nasal titer at 5 mg/kg (i.p.), with nasal titer measured at 4.90 log10 total PFU.
Reduced lung titer by 0.59 log10 from control at 5 mg/kg (i.p.), with lung titer at 4.3 log10 PFU/g.
Showed no significant reduction in nasal titer at 12 mg/kg (i.m.), with nasal titer measured at 4.45 log10 total PFU.
Reduced lung titer by 1.21 log10 (17-fold) from control at 12 mg/kg (i.m.), with lung titer at 3.7 log10 PFU/g.
Accession
A0A0X8XRK2
Target
RSV-F
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Crowe JE Jr, et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis. 1998;177(4):1073-1076. [Content Brief]
[2]. Zeitlin L, et al. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013;5(2):263-269. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NIAID RSVF2-5 Related Classifications
HY-P992423 Related Classifications
Powered by Bioz